A detailed history of Boston Partners transactions in Biote Corp. stock. As of the latest transaction made, Boston Partners holds 615,337 shares of BTMD stock, worth $4.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
615,337
Previous 669,728 8.12%
Holding current value
$4.07 Million
Previous $5 Million 31.37%
% of portfolio
0.0%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$5.33 - $8.36 $289,904 - $454,708
-54,391 Reduced 8.12%
615,337 $3.43 Million
Q2 2024

Aug 13, 2024

SELL
$5.44 - $7.47 $239,430 - $328,777
-44,013 Reduced 6.17%
669,728 $5 Million
Q1 2024

May 13, 2024

SELL
$3.79 - $6.91 $440,344 - $802,845
-116,186 Reduced 14.0%
713,741 $4.14 Million
Q4 2023

Feb 07, 2024

SELL
$4.43 - $5.81 $270,633 - $354,938
-61,091 Reduced 6.86%
829,927 $4.1 Million
Q3 2023

Nov 07, 2023

SELL
$4.73 - $7.83 $554,441 - $917,816
-117,218 Reduced 11.63%
891,018 $4.56 Million
Q2 2023

Aug 10, 2023

BUY
$5.27 - $6.9 $385,279 - $504,445
73,108 Added 7.82%
1,008,236 $6.82 Million
Q1 2023

May 09, 2023

BUY
$3.14 - $6.19 $2.94 Million - $5.79 Million
935,128 New
935,128 $5.79 Million

Others Institutions Holding BTMD

About biote Corp.


  • Ticker BTMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 7,574,270
  • Market Cap $50.1M
  • Description
  • biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biot...
More about BTMD
Track This Portfolio

Track Boston Partners Portfolio

Follow Boston Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

News

Stay updated on Boston Partners with notifications on news.